share_log

Is MariMed A Safe Haven In The Wake Of Florida's Cannabis Legalization Defeat?

Benzinga ·  Dec 4, 2024 09:32

Cannabis companyMariMed Inc.(NASDAQ:MRMD) released its Q3 2024 results on November 6, announcing revised guidance for the fiscal year. While the company expects an 18–20% decline in EBITDA – down from its prior projection of flat to 2% growth – it raised its sales guidance to a 6–8% increase, up from 5–7%. These adjustments align closely with earlier projections fromZuanic & Associates, a cannabis industry research firm.

  • Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter here. You can't afford to miss out if you're serious about the business.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment